Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
FibroGen Inc
FGENCurrent price
0.29 USD
+0.015 USD (+5.45%)
Last closed
0.27 USD
Company
www.fibrogen.com
ISIN
US31572Q8087
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
28 892 538 USD
Yield for 12 month
-74.89 %
1Y
3Y
5Y
10Y
15Y
FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 350 Bay Street, San Francisco, CA, United States, 94133
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.00 USDP/E ratio
–Dividend Yield
–Current Year
+29 621 000 USD
Last Year
+147 752 000 USD
Current Quarter
-123 256 000 USD
Last Quarter
+46 333 000 USD
Current Year
+14 060 000 USD
Last Year
+128 904 000 USD
Current Quarter
-102 590 000 USD
Last Quarter
+41 038 000 USD
Key Figures FGEN
1 year
3 years
5 years
10 years
EBITDA
-128 270 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-25.66 %
PEG Ratio
–
Return On Equity TTM
-1 015.79 %
Wall Street Target Price
10.00 USD
Revenue TTM
29 621 000 USD
Book Value
-2.24 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
15.40 %
Dividend Yield
–
Gross Profit TTM
-81 632 000 USD
Earnings per share
-1.53 USD
Diluted Eps TTM
-1.53 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
53.60 %
Profit Margin
-160.63 %
Dividend Analytics FGEN
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History FGEN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation FGEN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
61.35
Enterprise Value Revenue
1.74
Price Sales TTM
0.98
Enterprise Value EBITDA
-0.17
Price Book MRQ
53.83
Financials FGEN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators FGEN
For 52 weeks
0.18 USD
1.74 USD
50 Day MA
0.40 USD
Shares Short Prior Month
4 978 990
200 Day MA
0.47 USD
Short Ratio
2.92
Shares Short
4 668 238
Short Percent
5.44 %
BeatStart